As severe winter weather impacts pharmacies across the country, AIS Healthcare is drawing on its robust emergency preparedness and taking additional measures to continue to deliver vital, patient-specific medications on time.
If you believe you will be impacted by the storms, please call us at 877.443.4006.
Dallas, Texas—In the wake of a severe winter storm that has affected both the pharmaceutical supply chain as well as national shipping services, AIS Healthcare has gone above and beyond to ensure all of its patients have uninterrupted access to critical targeted drug delivery (TDD), infusion and ophthalmics medications.
AIS Healthcare is always prepared for inclement weather. Its seven pharmacies are spread across six states and have production and operational redundancies, allowing medication compounding and delivery to continue even if severe weather impacts one or more locations. The pharmacy teams in all seven locations continuously monitor the weather and potential disruption to distribution services and adjust shipping accordingly. In addition, extended Beyond-Use Dates on many patient-specific prescriptions allow providers to order prescriptions in advance of severe weather and offer flexibility in scheduling appointments during storms.
AIS Healthcare also has a robust emergency contingency plan, which accounts for a variety of natural disasters and severe weather. Over the past seven days, this plan has been activated and AIS Healthcare teams have been proactively partnering with providers to get prescriptions to patients.
This emergency contingency plan includes:
AIS Healthcare has also taken some extraordinary steps to deliver medication on time, including chartering cross-country flights to avoid shipping delays. The TDD division recently sent more than 40 prescriptions via private plane to waiting providers and patients in Indiana and Kentucky. When the ophthalmics team identified more than 30 surgical patients who could be impacted by shipping delays, another private plane was chartered to fly the medications to the divisional headquarters in Maryland, where the medication could be more quickly delivered to the affected patients.
To support its own staff during the winter storm, AIS Healthcare has provided hotel accommodations and personal generators to employees in need. This ensures that all staff members are safe and able to continue to provide high-quality care and support during this time.
“I am proud of everything we have done to ensure all of our patients have the medication they need, when they need it,” said Simon Castellanos, Chief Executive Officer of AIS Healthcare. “We will always be the pharmacy provider that does more—for our patients, our providers and our staff.”
About AIS Healthcare
Advancing quality. Improving lives.
As the leading provider of targeted drug delivery (TDD), infusion care and ophthalmic solutions, AIS Healthcare is committed to doing more of what matters. From pharmacies that put patient safety first to comprehensive services that enhance the entire care experience, we go beyond the expected in everything we do.
Learn more at aiscaregroup.com
Contact:
Simon Castellanos
877.443.4006
AIS Healthcare is committed to doing more of what matters, not only to improve quality in healthcare but also to improve lives in our communities. Now, we’re honoring this commitment by supporting two organizations dedicated to increasing opportunity and reducing inequality: The Breonna Taylor Memorial Scholarship Fund in Nursing and Feeding America.
AIS Healthcare is matching all employee donations to each organization, up to $50,000 total, for a potential $100,000 impact.
“These two partnerships are just the beginning,” said Simon Castellanos, Chief Executive Officer of AIS Healthcare. “We will continue to find ways to help create a more just, more equitable world. We will continue to do what’s right, not just what’s expected, at a time when doing what’s right is more important than ever.”
The Breonna Taylor Memorial Scholarship Fund in Nursing
In March 2020, Breonna Taylor, an emergency room technician at University of Louisville Health, was killed by police officers serving a no-knock warrant at her home. To honor her memory, UofL Health has created a nursing scholarship in her name.
The Breonna Taylor Memorial Scholarship Fund in Nursing will cover four years of tuition and fees. Preference will be given to Black female residents of Kentucky.
More than 325 patients in Kentucky receive in-home nursing care from AIS Healthcare. We are proud to increase access to nursing education in this community while remembering the life of a dedicated healthcare worker.
Feeding America
More and more Americans are going hungry due to the COVID-19 pandemic. Feeding America, a national network of food banks, estimates that more than 50 million people across the country may experience food insecurity this year, including 17 million children.
Every dollar donated to Feeding America helps provide at least 10 meals. AIS Healthcare’s efforts could give half a million meals to Americans in need.
About AIS Healthcare
Advancing quality. Improving lives.
As the leading provider of targeted drug delivery (TDD), infusion care and ophthalmic solutions, AIS Healthcare is committed to doing more of what matters. From pharmacies that put patient safety first to comprehensive services that enhance the entire care experience, we go beyond the expected in everything we do.
Learn more at aiscaregroup.com
Contact:
Simon Castellanos
877.443.4006
Dallas, TX- Advanced Infusion Care, a division of AIS Healthcare, now offers Cuvitru™, developed by Takeda for the treatment of patients with primary immunodeficiency (PI).
The nationally accredited home infusion teams at AIC collaborate closely with physicians to provide specialized in-home infusion services. This new therapy option, offered under a limited distribution partnership with Takeda, expands AIC’s ability to serve immunoglobulin (Ig) infusion patients.
“We’re proud to be able to add Cuvitru™ to our growing list of Ig infusion therapies,” said Jud Hall, President at AIC. “This new therapy from Takeda can help us provide additional treatment options for our PI patients.”
Cuvitru™ is indicated for the treatment of PI in adults and pediatric patients 2 years of age or older. Approved by the U.S Food and Drug Administration on September 14, 2016, the therapy is now available at all AIC locations.
Like all AIC patients, PI patients will receive a high level of care from AIC, including 24/7 access to clinical and support staff. Every patient is assigned a dedicated team of professionals, including clinical pharmacists, infusion nurse specialists, and intake managers to provide support throughout the treatment process.
For physicians, AIC is a full-service care delivery partner. We have contracts with multiple immunoglobulin suppliers, like Takeda. These contracts help us ensure prescribed therapies are always in stock. We also work directly with patients, insurance companies, and physician offices to secure all needed authorizations and complete paperwork.
AIS Healthcare is dually accredited by URAC and the Accreditation Commission for Health Care (ACHC).
Physicians interested in AIC care services should contact their AIC representatives to get started or visit us at www.aiscaregroup.com/our-divisions/infusion-care/
About AIS Healthcare
Advancing quality. Improving lives.
As the leading provider of targeted drug delivery (TDD), infusion care, and ophthalmic solutions, AIS Healthcare is committed to doing more of what matters. From pharmacies that put patient safety first to comprehensive services that enhance the entire care experience, we go beyond the expected in everything we do.
Learn more at aiscaregroup.com.
About Takeda
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.